In the midst of trying to woo one rival and fend off another, Mylan on Tuesday reported sharply lower profits for the first quarter while CEO Heather Bresch emphasized the generic drug company’s “steadfast” commitment to winning the hand of Ireland-based drug maker Perrigo.

“We have long believed the combination of Perrigo and Mylan represents an extraordinary opportunity,” Ms. Bresch said during a conference call with analysts.

She said Mylan was confident of closing the deal before the end of the year, despite Mylan’s advances being spurned by Perrigo’s board for the third time last week.

At the same time, Ms. Bresch said the company would have no further comment on the $82-per-share takeover offer from Israel’s Teva Pharmaceutical Industries, which Mylan rejected last week.

Advertise with us

“We believe our board’s response speaks for itself,” she said.

Mylan, which is run from its operations base in Cecil, has repeatedly said that combining with the world’s biggest generic drug company was “without sound industrial logic.” The company also has argued that the merger would not win antitrust clearances and that the two companies did not fit culturally.

Meanwhile, Teva on Tuesday issued a statement reiterating its resolve in combining with Mylan.

“We are committed to making this transaction a reality ... as soon as possible,” the statement said.

Teva also said it had “carefully studied the regulatory and antitrust aspects” of the proposed transaction and was confident of gaining approval.

Advertise with us

Mylan’s profits skidded 51 percent in the first quarter to $56.6 million, down from $115.9 million a year earlier. Results were dragged down by costs related to the acquisition of a major chunk of Abbott Laboratories non-U.S. operations, which was completed in February.

Per-share earnings fell 55 percent to 13 cents from 29 cents. Factoring out special items, adjusted profits rose 6 percent to 70 cents per share, in line with analysts’ estimates. Revenue for the quarter climbed 9 percent to $1.87 billion from $1.72 billion.

Results were released after the close of the stock market. Mylan’s shares slipped 16 cents, or .22 percent, to close Tuesday at $72.89.

Patricia Sabatini: psabatini@post-gazette.com or 412-263-3066.